INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Debt / NOTE 3.250% 7/0
Market price (% of par)
94.68%
Total 13F principal
$82,778,227
Principal change
-$331,915
Total reported market value
$79,161,051
Number of holders
24
Value change
-$6,465
Number of buys
7
Number of sells
9

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q4 2021

As of 31 Dec 2021, INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by 24 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $82,778,227 in principal (par value) of the bond. The largest 10 bondholders included DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), OAKTREE CAPITAL MANAGEMENT LP, MORGAN STANLEY, Kohlberg Kravis Roberts & Co. L.P., BlackRock Inc., Saltoro Capital, LP, STATE STREET CORP, Russell Investments Group, Ltd., Parallax Volatility Advisers, L.P., and L & S Advisors Inc. This page lists 24 institutional bondholders reporting positions for the Q4 2021 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.